Market capitalisation
?
Share price multiplied by shares outstanding. It does not measure company cash.
Company analysis·PFE
Preparing the analysis
We’re preparing the company’s analysis.
NYSE·PFE
Pfizer Inc.
Share price$29.06Price as of: Nov 9, 2026
Pfizer Inc. (PFE) is a company listed on NYSE, classified under Drug Manufacturers - General.
Pfizer is a global pharmaceutical company engaged in developing, manufacturing, and marketing medicines and vaccines worldwide.
Revenue · FY 2025
?
Sales generated during the period, before costs and expenses.
Net margin · FY 2025
?
Net income as a proportion of revenue.
“Our take” and other explanations are generated with artificial intelligence from the data, without human review of each text. They are descriptive, not recommendations. Learn more
Explore questions
P1 · What does it do and how does it make money?
Of every $100 it takes in,98 come from Biopharma Segment.
Biopharma Segment is its largest source of revenue (97.8%), followed by Segment Reporting, Reconciling Item, Corporate Nonsegment (2.2%). Here you will see what it sells, where, and how that mix is changing.
$63bnrevenue in FY 2025
2business lines with data
59%of sales, in UNITED STATES
Full fiscal year ended Dec 31, 2025
After that close
Q2 2026, ended Jun 28, 2026: total revenue +2.6% against the same quarter a year earlier.
This is the revenue of the whole company. The split by lines and regions on this page is still that of the full fiscal year.01How it makes money
The data does not separate products from services.
Not all revenue behaves the same way. A one-off sale depends on someone buying again; a service is billed again and again while the customer stays.
Its business lines · FY 2025
02Where revenue comes from
A single line brings in half or more.
Each rectangle is a business line and its size is the share of revenue it brings in. Select one to see the detail.
No room for a label in the mosaic
Area = share of total revenue for the year. It does not show profit: the company does not report what each line earns.
What is a segment's weight?
The part of everything the company takes in that comes from that line. If a line weighs 49%, then of every 100 in sales, 49 come from it.
How to read it
The more a line weighs, the more revenue depends on it. A high weight is neither good nor bad by itself: it shows where to look first.
03Where sales come from
It depends on one main market.
UNITED STATES is its largest market, with 59.2% of sales. Each square is a region and its area is what it sells there.
Regions from largest to smallest · FY 2025
04How the mix is changing
The mix barely changes.
Weight of each part in 2024 and in 2025. A line gains weight when it grows faster than the total.
pp = percentage points: the difference between two percentages (from 25% to 27% is 2 pp).
05Read with care
What we can deduce from the data. And what we cannot.
We can deduceWe cannot conclude
01
The company relies almost entirely on the Biopharma Segment, which still represents 97.8% of revenue in FY 2025.
That any other line ever provided stability: the totals and history show none are large enough to offset a drop in the main line.
02
Only Emerging Markets showed notable growth (+4.9%), but its share is far less than that of the US or Developed Rest Of World.
That all regions contributed equally to the total: the US decline shapes the overall trend despite isolated increases elsewhere.
03
Net margin slips from 12.6% to 12.4%: profitability tracks with sales decline, with no sign from lines or regions of any offsetting effect.
That a particular line or region underpinned profit: margin and profit share by line or region are unknown.
Our take
Pfizer is almost entirely dependent on its Biopharma Segment and the US, with too little base elsewhere to soften downturns.
- 01Shown by the figures
Extremely high concentration, limited balancing
Nearly all business depends on Biopharma Segment and the US. Growth in emerging markets is nowhere near enough to offset weakness in its main source, whether by line or region. Margin follows sales pressure. There’s no sign that smaller lines cushion these swings.
What is not proven
Without profit split by segment, it remains unclear if any secondary region or line helps hold up earnings when the main ones falter.
See the calculations behind it
- Dependence on Biopharma Segment barely changes: 98.1% of revenue in FY 2024 and 97.8% in FY 2025.
- United States brings 59.2% of sales (60.8% in FY 2024). The fastest-growing region is Emerging Markets: +4.9% against −1.6% overall.
- Biopharma Segment weighs more than all the other lines together: 97.8% of revenue in FY 2025.
With data to Nov 4, 2026. Analysis written by a language model from our calculations, which supply every figure. It is not investment advice.
Next step